Background: Psoriasis is a multifactorial chronic inflammatory skin disease characterized by erythemato-squamous lesions with a chronic relapsing course. The desease clinical activity (PASI) and the patient's quality of life (DLQI) are the main elements to assess for setting up a correct therapeutic management. Objectives: The aim of the study was to evaluate the management of the patient with moderate-severe psoriasis in therapy with biological drugs and to establish the difference in the achievement of PASI 90 and DLQI 0-1 between a group of patients treated with only biological drugs and a group of patients receiving biologic therapy in combination with a topical ointment. Methods: We conducted a prospective, observational real-life study enrolling 60 patients with moderate to severe psoriasis and divided in two groups: Group A patients treated with biological drugs, Group B patiens treated with biological drugs in association with an ointment composed of betamethasone, salicylic acid and ammonium sulpho-ichtyolate, applied 2 times a day. PASI and DLQI were evaluated at study beginning (T0) for both study groups, after 12 weeks (T3) for sample in therapy with biological drugs and after 24 weeks (T6) for sample in co-medication therapy. Results: The two-way ANOVA method was used to evaluate the standard deviations (SD): at T3 and T6 Group B obtained a significant PASI reduction and improvement of DLQI (* p value <0.05) compared to Group A. Conclusions: Our study shown that the patients treated with biologics in co-medication with topical therapy reached a significantly higher PASI and DQLI compared with those treated with only biologics. Furthermore we observed that the association with topical oinment showed more efficacy in the treatment of areas such as palm-plantar region, that is often difficult-to-treat region, even for biologic drugs.

Benefit of a topic ointment as co-medication with biologic drugs for the management of moderate-severe psoriasis. A prospective, observational real-life study / Bernardini, N; Skroza, N; Tolino, E; Marchesiello, A; Mambrin, A; Balduzzi, V; Michelini, S; Maddalena, P; Volpe, S; Proietti, I; Potenza, C.. - In: LA CLINICA TERAPEUTICA. - ISSN 0009-9074. - 171:4(2020), pp. 310-315. [10.7417/CT.2020.2234]

Benefit of a topic ointment as co-medication with biologic drugs for the management of moderate-severe psoriasis. A prospective, observational real-life study

Bernardini N;Skroza N;Tolino E;Mambrin A;Maddalena P;Volpe S;Proietti I;Potenza C.
2020

Abstract

Background: Psoriasis is a multifactorial chronic inflammatory skin disease characterized by erythemato-squamous lesions with a chronic relapsing course. The desease clinical activity (PASI) and the patient's quality of life (DLQI) are the main elements to assess for setting up a correct therapeutic management. Objectives: The aim of the study was to evaluate the management of the patient with moderate-severe psoriasis in therapy with biological drugs and to establish the difference in the achievement of PASI 90 and DLQI 0-1 between a group of patients treated with only biological drugs and a group of patients receiving biologic therapy in combination with a topical ointment. Methods: We conducted a prospective, observational real-life study enrolling 60 patients with moderate to severe psoriasis and divided in two groups: Group A patients treated with biological drugs, Group B patiens treated with biological drugs in association with an ointment composed of betamethasone, salicylic acid and ammonium sulpho-ichtyolate, applied 2 times a day. PASI and DLQI were evaluated at study beginning (T0) for both study groups, after 12 weeks (T3) for sample in therapy with biological drugs and after 24 weeks (T6) for sample in co-medication therapy. Results: The two-way ANOVA method was used to evaluate the standard deviations (SD): at T3 and T6 Group B obtained a significant PASI reduction and improvement of DLQI (* p value <0.05) compared to Group A. Conclusions: Our study shown that the patients treated with biologics in co-medication with topical therapy reached a significantly higher PASI and DQLI compared with those treated with only biologics. Furthermore we observed that the association with topical oinment showed more efficacy in the treatment of areas such as palm-plantar region, that is often difficult-to-treat region, even for biologic drugs.
2020
HIV; psoriasis; psoriasis treatment
01 Pubblicazione su rivista::01a Articolo in rivista
Benefit of a topic ointment as co-medication with biologic drugs for the management of moderate-severe psoriasis. A prospective, observational real-life study / Bernardini, N; Skroza, N; Tolino, E; Marchesiello, A; Mambrin, A; Balduzzi, V; Michelini, S; Maddalena, P; Volpe, S; Proietti, I; Potenza, C.. - In: LA CLINICA TERAPEUTICA. - ISSN 0009-9074. - 171:4(2020), pp. 310-315. [10.7417/CT.2020.2234]
File allegati a questo prodotto
File Dimensione Formato  
Bernardini_Benefit_2020pdf

accesso aperto

Note: http://www.clinicaterapeutica.it/2020/171/4/07_BERNARDINI.pdf
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 298.95 kB
Formato Unknown
298.95 kB Unknown

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1572238
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact